Security
Kalaris Therapeutics, Inc. Common Stock · KLRS
KLRSNASDAQCommon stockCurrentCIK 1754068Updated Oct 27, 2026
Name history
Allovir, Inc. · through Mar 12, 2025ViraCyte, Inc. · through Oct 2, 2018
KLRS price & chart
Loading TradingView…
NASDAQ:KLRS on TradingView ↗About the company
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.
In the news
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling ↗
Recent filings
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 81,175,000Source | 122,530,000Source | 99,539,000Source | 92,842,000Source | 130,987,000Source | 109,805,000Source | 103,092,000Source | 144,143,000Source | 121,736,000Source | 118,546,000Source | 190,796,000Source | 277,079,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 930,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 42,387,000Source | 1,913,000Source | 43,173,000Source | 88,426,000Source | 6,239,000Source | 34,427,000Source | 100,965,000Source | 5,227,000Source | 98,054,000Source | 118,289,000Source | 90,121,000Source | 106,092,000Source |
| Assets, CurrentUSD | 78,183,000Source | 122,530,000Source | 95,921,000Source | 91,651,000Source | 129,938,000Source | 98,465,000Source | 102,182,000Source | 141,482,000Source | 118,809,000Source | 118,546,000Source | 187,635,000Source | 243,052,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,184,000Source | 626,000Source | 1,869,000Source | 3,225,000Source | 230,000Source | 861,000Source | 1,217,000Source | 771,000Source | 827,000Source | 257,000Source | 3,486,000Source | 7,100,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,516,000Source | — | 1,389,000Source | — | 495,000Source | 1,433,000Source | — | 2,107,000Source | 1,475,000Source | — | 2,187,000Source | 31,633,000Source |
| Other Assets, NoncurrentUSD | 976,000Source | — | 1,729,000Source | 691,000Source | — | 1,753,000Source | 410,000Source | — | 953,000Source | — | 122,000Source | 612,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 39,310,000Source | 1,412,000Source | 41,867,000Source | 39,727,000Source | 10,695,000Source | 41,248,000Source | 39,218,000Source | 23,703,000Source | 42,922,000Source | 5,239,000Source | 45,015,000Source | 52,560,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 2,000Source | 11,000Source | 2,000Source | 2,000Source | 11,000Source | 2,000Source | 2,000Source | 11,000Source | 2,000Source | 0Source | 11,000Source | 9,000Source |
| Additional Paid in CapitalUSD | 191,858,000Source | 817,935,000Source | 240,113,000Source | 191,220,000Source | 812,988,000Source | 239,459,000Source | 190,629,000Source | 807,059,000Source | 238,805,000Source | 828,404,000Source | 802,025,000Source | 690,753,000Source |
| Retained Earnings (Accumulated Deficit)USD | -150,001,000Source | -696,694,000Source | -182,370,000Source | -138,107,000Source | -692,568,000Source | -170,855,000Source | -126,757,000Source | -686,492,000Source | -159,999,000Source | -714,962,000Source | -656,193,000Source | -465,775,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 6,000Source | -134,000Source | -73,000Source | — | -139,000Source | -49,000Source | — | -138,000Source | 6,000Source | -135,000Source | -62,000Source | -468,000Source |
| Stockholders' Equity Attributable to ParentUSD | 41,865,000Source | -89,380,000Source | 57,672,000Source | 53,115,000Source | -51,527,000Source | 68,557,000Source | 63,874,000Source | -47,540,000Source | 78,814,000Source | 113,307,000Source | 145,781,000Source | 224,519,000Source |
| Liabilities and EquityUSD | 81,175,000Source | 122,530,000Source | 99,539,000Source | 92,842,000Source | 130,987,000Source | 109,805,000Source | 103,092,000Source | 144,143,000Source | 121,736,000Source | 118,546,000Source | 190,796,000Source | 277,079,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,065,000Source | 1,412,000Source | 8,738,000Source | 7,651,000Source | 2,359,000Source | 8,079,000Source | 7,142,000Source | 7,656,000Source | 9,714,000Source | 5,239,000Source | 28,367,000Source | 24,338,000Source |
| Operating Lease, Liability, CurrentUSD | 376,000Source | — | 347,000Source | — | 667,000Source | 317,000Source | — | 2,295,000Source | 316,000Source | — | 10,781,000Source | 7,165,000Source |
| Accounts Payable, CurrentUSD | 494,000Source | 51,000Source | 1,124,000Source | 3,680,000Source | 110,000Source | 905,000Source | 2,374,000Source | 765,000Source | 1,281,000Source | 247,000Source | 6,761,000Source | 3,004,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,169,000Source | — | 1,053,000Source | — | 8,336,000Source | 1,093,000Source | — | 16,047,000Source | 1,132,000Source | — | 16,648,000Source | 28,222,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 1,361,000Source | — | — | 1,582,000Source | — | — | 4,596,000Source | — | 4,992,000Source | 10,086,000Source | 13,985,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 77,000Source | 121,900,000Source | 93,500,000Source | — | 129,600,000Source | 104,900,000Source | — | 140,500,000Source | 118,000,000Source | 118,300,000Source | 183,900,000Source | 233,800,000Source |
| Short-term InvestmentsUSD | 34,612,000Source | 4,995,000Source | 50,365,000Source | — | 24,871,000Source | 62,788,000Source | — | 54,491,000Source | 19,928,000Source | 0Source | 93,822,000Source | 127,703,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -10,856,000Source | -10,196,000Source | -43,438,000Source | -58,769,000Source | -190,418,000Source | -168,710,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 398,000Source | 723,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 580,000Source | 374,000Source | 1,936,000Source | 26,347,000Source | 40,779,000Source | 41,315,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -376,000Source | 934,000Source | -88,000Source | — | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -11,581,000Source | -7,441,000Source | -38,370,000Source | -67,705,000Source | -124,451,000Source | -142,052,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -50,350,000Source | — | -19,723,000Source | 95,000,000Source | 37,985,000Source | -80,478,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 200,000Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -1,695,000Source | 107,267,000Source | 155,007,000Source | 21,000Source | 70,495,000Source | 126,961,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -63,626,000Source | 99,826,000Source | 96,914,000Source | 27,316,000Source | -15,971,000Source | -95,569,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 42,887,000Source | 1,913,000Source | 43,673,000Source | 88,926,000Source | 34,927,000Source | 101,465,000Source | 98,553,000Source | 118,289,000Source | 90,973,000Source | 106,944,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | 220,000Source | 613,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 638,000Source | 262,000Source | 644,000Source | 591,000Source | 580,000Source | 374,000Source | 1,936,000Source | 26,347,000Source | 40,779,000Source | 41,315,000Source |
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 500,000Source | 500,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 77,000Source | 121,900,000Source | 93,500,000Source | — | 104,900,000Source | — | 118,000,000Source | 118,300,000Source | 183,900,000Source | 233,800,000Source |
| DepreciationUSD | — | — | — | — | — | — | 10,000Source | — | 13,000Source | — | 400,000Source | 700,000Source |
| General and Administrative ExpenseUSD | — | — | 3,615,000Source | 1,829,000Source | 3,368,000Source | 3,816,000Source | 4,261,000Source | 4,324,000Source | 15,399,000Source | 42,916,000Source | 48,261,000Source | 52,332,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | -126,000Source | -265,000Source |
| InterestExpenseNonoperatingUSD | — | — | 0Source | 815,000Source | 0Source | 0Source | 0Source | 1,443,000Source | 1,443,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | 1,494,000Source | — | — | — | — | — | 5,486,000Source | 5,734,000Source | 1,876,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,894,000Source | -38,084,000Source | -11,515,000Source | -11,350,000Source | -10,856,000Source | -10,196,000Source | -43,438,000Source | -58,769,000Source | -190,418,000Source | -168,710,000Source |
| Nonoperating Income (Expense)USD | — | — | 847,000Source | -235,000Source | 871,000Source | 906,000Source | 977,000Source | 158,000Source | 2,714,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 12,741,000Source | 37,849,000Source | 12,386,000Source | 12,256,000Source | 11,833,000Source | 10,354,000Source | 46,152,000Source | 65,441,000Source | 199,901,000Source | 171,202,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 6,600,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 16,600,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 847,000Source | 31,000Source | 871,000Source | 906,000Source | 977,000Source | 193,000Source | 2,749,000Source | 1,186,000Source | 3,623,000Source | 351,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 42,000,000Source | — | — | 126,425,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 20,000,000Source | — | 15,000,000Source | 95,000,000Source | 163,812,000Source | 148,328,000Source |
| Restructuring CostsUSD | — | — | — | 83,000Source | — | — | — | — | — | 10,185,000Source | — | — |
| Marketable Securities, Unrealized Gain (Loss) | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -12,741,000Source | -37,849,000Source | -12,386,000Source | -12,256,000Source | -11,833,000Source | -10,354,000Source | -46,152,000Source | -65,441,000Source | -199,901,000Source | -171,202,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 847,000Source | 31,000Source | 871,000Source | 906,000Source | 977,000Source | 193,000Source | 2,749,000Source | 1,186,000Source | 3,623,000Source | 351,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -43,438,000Source | -58,769,000Source | -190,544,000Source | -168,975,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | -126,000Source | -265,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,894,000Source | -38,084,000Source | -11,515,000Source | -11,350,000Source | -10,856,000Source | -10,196,000Source | -43,438,000Source | -58,769,000Source | -190,418,000Source | -168,710,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.64Source | -28.16Source | -0.48Source | -0.61Source | -0.46Source | -2.52Source | -2.85Source | -11.73Source | -1.83Source | -2.2Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.64Source | -28.16Source | -0.48Source | -0.61Source | -0.46Source | -2.52Source | -2.85Source | -11.73Source | -1.83Source | -2.2Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 18,701,708Source | 1,352,265Source | 23,797,306Source | 18,701,286Source | 23,723,618Source | 4,053,140Source | 15,267,817Source | 5,008,449Source | 104,057,220Source | 76,654,856Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 18,701,708Source | 1,352,265Source | 23,797,306Source | 18,701,286Source | 23,723,618Source | 4,053,140Source | 15,267,817Source | 5,008,449Source | 104,057,220Source | 76,654,856Source |
| Interest Expense (non-operating)USD | — | — | 0Source | 815,000Source | 0Source | 0Source | 0Source | 1,443,000Source | 1,443,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 500,000Source | 500,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | -126,000Source | -265,000Source |
| General and Administrative ExpenseUSD | — | — | 3,615,000Source | 1,829,000Source | 3,368,000Source | 3,816,000Source | 4,261,000Source | 4,324,000Source | 15,399,000Source | 42,916,000Source | 48,261,000Source | 52,332,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -43,438,000Source | -57,118,000Source | -376,152,000Source | -113,389,000Source |
| Interest ExpenseUSD | — | — | — | 815,000Source | 0Source | 0Source | 0Source | 1,443,000Source | 1,443,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | 1,494,000Source | — | — | — | — | — | 5,486,000Source | 5,734,000Source | 1,876,000Source |
| Management Fee ExpenseUSD | — | — | — | 0Source | 20,000Source | — | 20,000Source | 10,000Source | 100,000Source | 100,000Source | 400,000Source | 500,000Source |
| Nonoperating Income (Expense)USD | — | — | 847,000Source | -235,000Source | 871,000Source | 906,000Source | 977,000Source | 158,000Source | 2,714,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 12,741,000Source | 37,849,000Source | 12,386,000Source | 12,256,000Source | 11,833,000Source | 10,354,000Source | 46,152,000Source | 65,441,000Source | 199,901,000Source | 171,202,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 6,600,000Source |
| Other General and Administrative ExpenseUSD | — | — | 2,478,000Source | 1,249,000Source | 2,148,000Source | 2,722,000Source | 2,697,000Source | 3,647,000Source | 10,952,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 9,126,000Source | 36,020,000Source | 9,018,000Source | 8,440,000Source | 7,572,000Source | 6,030,000Source | 30,753,000Source | 12,340,000Source | 133,070,000Source | 118,870,000Source |
| Restructuring CostsUSD | — | — | — | 83,000Source | — | — | — | — | — | 10,185,000Source | — | — |
Offerings
Registration 333-294881
Registration 333-294883
Registration 333-283678
Filing attachments
d114296dex991.htm · 8-K · 2026-08-11
EX-99.1 2 d114296dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund operations into the fourth quarter of 2027 and through key cli…
Read attachment ↗d125006dex991.htm · 8-K · 2026-07-17
EX-99.1 2 d125006dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027 BERKELEY HEIGHTS, N.J., July 17, 2026 (GLOBE NEWSWIRE) - Kalar…
Read attachment ↗d125006dex992.htm · 8-K · 2026-07-17
EX-99.2 3 d125006dex992.htm EX-99.2 EX-99.2 July 2026 Kalaris Company Overview Exhibit 99.2 Forward-Looking Statements & Disclaimer This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risk and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including statement…
Read attachment ↗d24879dex991.htm · 8-K · 2026-05-12
EX-99.1 2 d24879dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials remain on track for 2027 year-end initiation $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 is …
Read attachment ↗d20326dex43.htm · S-3 · 2026-04-03
Exhibit 4.3 KALARIS THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Section of Trust Indenture Act Indenture of 1939, as amended ───────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) In…
Read attachment ↗d20326dex44.htm · S-3 · 2026-04-03
Exhibit 4.4 KALARIS THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act Section of of 1939, as amended Indenture ──────────────────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) …
Read attachment ↗